This Article Full Text (PDF) All Versions of this Article: 1758834009347923v1 1/3/137    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Peled, N. Articles by Hirsch, F. R. Social Bookmarking                         What's this?

Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer

University of Colorado Denver, Division of Medical Oncology, 12801 E 17th Avenue, Mail Stop 8177 Aurora, CO, 80045 USA, fred.hirsch{at}uchsc.edu

Koichi Yoshida

Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA

Murry W. Wynes

Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA

Fred R. Hirsch

Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA

Epidermal growth factor receptor (EGFR) related therapies - mainly tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib, but also monoclonal antibodies targeting EGFR, for example, cetuximab - have been investigated in numerous settings in non-small cell lung cancer (NSCLC) and in different combinations. The overall clinical benefit of EGFR TKI therapy is roughly 10-30%, with higher benefit in nonsmoker Asiatic women with EGFR-mutated adenocarcinoma. Currently, there are several biomarkers that are able to direct and predict the yield of EGFR-related therapies in NSCLC. These include EGFR mutation status, EGFR protein expression, EGFR gene copy number and a serum proteomic marker (Veristrat^®, Biodesix; CO). The usage of such biomarkers is important from many aspects. First, it helps clinicians to make the right treatment decisions and second, it leads to a wiser usage of financial resources. This review will focus on EGFR-related biomarkers for their prognostic power and their ability to predict clinical benefit from EGFR-related therapy.

Key Words: non-small cell lung cancer • epidermal growth factor receptor • biomarkers

This version was published on November 1, 2009

Therapeutic Advances in Medical Oncology, Vol. 1, No. 3, 137-144 (2009)
DOI: 10.1177/1758834009347923


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?